PDK1 Inhibitor BX795 Improves Cisplatin and Radio-Efficacy in Oral Squamous Cell Carcinoma by Downregulating the PDK1/CD47/Akt-Mediated Glycolysis Signaling Pathway
<b>Background</b>: Oral squamous cell carcinoma (OSCC) has a high prevalence and predicted global mortality rate of 67.1%, necessitating better therapeutic strategies. Moreover, the recurrence and resistance of OSCC after chemo/radioresistance remains a major bottleneck for its effective...
Guardado en:
Autores principales: | Shin Pai, Vijesh Kumar Yadav, Kuang-Tai Kuo, Narpati Wesa Pikatan, Chun-Shu Lin, Ming-Hsien Chien, Wei-Hwa Lee, Michael Hsiao, Shao-Chih Chiu, Chi-Tai Yeh, Jo-Ting Tsai |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
MDPI AG
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/a1855a558c4e4773ac1ec6099f77d687 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Circ_0091579 enhances the malignancy of hepatocellular carcinoma via miR-1287/PDK2 axis
por: Shu Junwei, et al.
Publicado: (2021) -
BX-795 inhibits neuroblastoma growth and enhances sensitivity towards chemotherapy
por: Rameswari Chilamakuri, et al.
Publicado: (2022) -
Involvement of Non-Coding RNAs in Chemo- and Radioresistance of Nasopharyngeal Carcinoma
por: Xiao J, et al.
Publicado: (2021) -
N 6 -methyladenosine regulates glycolysis of cancer cells through PDK4
por: Zihan Li, et al.
Publicado: (2020) -
HIF-1α-PDK1 axis-induced active glycolysis plays an essential role in macrophage migratory capacity
por: Hiroaki Semba, et al.
Publicado: (2016)